Mosby's 2014 Nursing Drug Reference (338 page)

BOOK: Mosby's 2014 Nursing Drug Reference
5.12Mb size Format: txt, pdf, ePub
ads

Canada only   Side effects:
italics
= common;
bold
= life-threatening   
Nurse Alert

pseudoephedrine nasal
agent

 

psyllium (
OTC
, Rx)

(sill′ee-um)

Hydrocil, Leader Fiber Laxative, Metamucil, Natural Fiber, Natural Vegetable Fiber, Reguloid, Wal-Mucil

Func. class.:
Bulk laxative

Chem. class.:
Psyllium colloid

ACTION:

Bulk-forming laxative

USES:

Chronic constipation, ulcerative colitis

Unlabeled uses:
Diarrhea, diverticulosis, irritable bowel syndrome, hypercholesterolemia

CONTRAINDICATIONS:

Hypersensitivity, intestinal obstruction, abdominal pain, nausea, vomiting, fecal impaction

Precautions:
Pregnancy (C)

DOSAGE AND ROUTES
Calculator

• Adult:
PO
1-2 tsp in 8 oz water bid or tid then 8 oz water or 1 premeasured packet in 8 oz water bid or tid, then 8 oz water

• Child
>
6 yr:
PO
1 tsp in 4 oz water at bedtime

Available forms:
Chew pieces 1.7, 3.4 g/piece; effervescent powder 3.4, 3.7 g/
packet; powder 3.3, 3.4, 3.5, 4.94 g/tsp; wafers 3.4 g/wafer

Administer:
PO route

• 
Alone for better absorption, separate from other products by 1-2 hr

• 
In morning or evening (oral dose)

• 
Immediately after mixing with water or will congeal

• 
With 8 oz water or juice followed by another 8 oz of fluid

SIDE EFFECTS

GI:
Nausea, vomiting, anorexia, diarrhea
, cramps, intestinal esophageal blockage

PHARMACOKINETICS

Onset 12-72 hr, excreted in feces, not absorbed in GI tract

INTERACTIONS

Decrease:
absorption of cardiac glycosides, oral anticoagulants, salicylates

Drug/Herb

Increase:
laxative effect—flax, senna

NURSING CONSIDERATIONS
Assess:

• 
Blood, urine electrolytes if used often

• 
I&O ratio to identify fluid loss

• 
Constipation:
cause of constipation; fluids, bulk, exercise missing; bowel sounds, distention, usual bowel function; color, consistency, amount

• 
Cramping, rectal bleeding, nausea, vomiting; product should be discontinued

Evaluate:

• 
Therapeutic response: decrease in constipation, decreased diarrhea with colitis

Teach patient/family:

• 
To maintain adequate fluid consumption

• 
That normal bowel movements do not always occur daily

• 
Not to use in presence of abdominal pain, nausea, vomiting

• 
To notify prescriber if constipation unrelieved or if symptoms of electrolyte imbalance occur: muscle cramps, pain, weakness, dizziness, excessive thirst

Canada only   Side effects:
italics
= common;
bold
= life-threatening   
Nurse Alert

pyridostigmine (Rx)

(peer-id-oh-stig′meen)

Mestinon, Mestinon Timespan, Regonol

Func. class.:
Cholinergic; anticholinesterase

Chem. class.:
Tertiary amine carbamate

ACTION:

Inhibits destruction of acetylcholine, which increases concentration at sites where acetylcholine is released; this facilitates the transmission of impulses across the myoneural junction

USES:

Nondepolarizing muscle relaxant antagonist, myasthenia gravis, pretreatment for nerve gas exposure (military only)

CONTRAINDICATIONS:

Bradycardia; hypotension; obstruction of intestine, renal system; bromide, benzyl alcohol sensitivity; adrenal insufficiency; cholinesterase inhibitor toxicity

Precautions:
Pregnancy (C), seizure disorders, bronchial asthma, coronary occlusion, hyperthyroidism, dysrhythmias, peptic ulcer, megacolon, poor GI motility

DOSAGE AND ROUTES
Calculator
Myasthenia gravis

• Adult:
PO
600 mg/day in 5-6 divided doses, max 1.5 g/day;
IM/IV
2 mg or 1/30 of
PO
dose;
SUS REL
180-540 mg/day or bid at intervals of ≥6 hr

• Child:
PO
7 mg/kg/day in 5-6 divided doses;
IM/IV
0.05-0.15 mg/kg/dose

Nondepolarizing neuromuscular blocker antagonist

• Adult:
0.6-1.2 mg IV
atropine then 0.1-0.25 mg/kg/dose

• Child:
IV
0.1-0.25 mg/kg/dose

Nerve gas exposure prophylaxis (military)

• Adult:
PO
30 mg q8hr if threat of exposure to Soman gas is anticipated; start several hours prior to exposure and discontinue upon exposure; after product is discontinued, give antidotes (atropine, pralidoxime)

Available forms:
Tabs 60 mg; ext rel tabs 180 mg; syr 60 mg/5 ml; inj 5 mg/ml

Administer:

• 
Only with atropine sulfate available for cholinergic crisis

• 
Only after all other cholinergics have been discontinued

• 
Increased doses for tolerance as ordered

• 
Larger doses after exercise or fatigue as ordered

• 
Do not break, crush, or chew sus rel tabs

PO route

• 
On empty stomach for better absorption

Direct IV route

• 
Undiluted (5 mg/ml), give through
Y
-tube or 3-way stopcock, give ≤0.5 mg/min (myasthenia gravis); 5 mg/min (reversal of nondepolarizing neuromuscular blockers)

Syringe compatibilities:
Glycopyrrolate

Y-site compatibilities:
Heparin, hydrocortisone, potassium chloride, vit B/C

SIDE EFFECTS

CNS:
Dizziness, headache, sweating, weakness,
seizures,
incoordination,
paralysis,
drowsiness, LOC

CV:
Tachycardia, dysrhythmias, bradycardia, AV block, hypotension, ECG changes,
cardiac arrest,
syncope

EENT:
Miosis, blurred vision, lacrimation, visual changes

GI:
Nausea, diarrhea, vomiting, cramps, increased salivary and gastric secretions, peristalsis

GU:
Urinary frequency, incontinence, urgency

INTEG:
Rash, urticaria, flushing

RESP:
Respiratory depression, bronchospasm, constriction, laryngospasm, respiratory arrest

SYST:
Cholinergic crisis

PHARMACOKINETICS

Metabolized in liver, excreted in urine (unchanged)

PO:
Onset 20-30 min, duration 3-6 hr

PO-EXT rel:
Onset 30-60 min, duration 6-12 hr

IM/IV/SUBCUT:
Onset 2-15 min, duration 2½-4 hr

INTERACTIONS

Increase:
action—succinylcholine

Decrease:
action—gallamine, metocurine, pancuronium, tubocurarine, atropine

Decrease:
pyridostigmine action—aminoglycosides, anesthetics, procainamide, quiNIDine, mecamylamine, polymyxin, magnesium, corticosteroids, antidysrhythmics, quinolones

NURSING CONSIDERATIONS
Assess:

• 
Myasthenia gravis:
fatigue, ptosis, diplopia, difficulty swallowing, SOB, hand/gait before, after product; improvement should be seen after 1 hr

• 
VS, respiration q8hr

• 
I&O ratio; check for urinary retention or incontinence

• 
Toxicity:
bradycardia, hypotension, bronchospasm, headache, dizziness, seizures, respiratory depression; product should be discontinued if toxicity occurs

Evaluate:

• 
Therapeutic response: increased muscle strength, hand grasp, improved gait, absence of labored breathing (if severe); reversal of nondepolarizing neuromus
cular blockers; prevention of nerve gas toxicity

Teach patient/family:

• 
Myasthenia gravis:
that product is not a cure, only relieves symptoms

• 
To wear emergency ID specifying myasthenia gravis, products taken

• 
To avoid driving, other hazardous activities until effect is known

• 
To report muscle weakness (cholinergic crisis or underdosage), bradycardia

• 
Not to drink alcohol

• 
To take with food to decrease gastric side effects

TREATMENT OF OVERDOSE:

Discontinue product, atropine 1-4 mg IV

Canada only   Side effects:
italics
= common;
bold
= life-threatening   
Nurse Alert

BOOK: Mosby's 2014 Nursing Drug Reference
5.12Mb size Format: txt, pdf, ePub
ads

Other books

In the House of the Interpreter by Ngugi wa'Thiong'o
Spellbound by Samantha Combs
In This Town by Beth Andrews
Savior in the Saddle by Delores Fossen
Winners by Danielle Steel
THE POLITICS OF PLEASURE by Mark Russell
Sacrifice of Love by Quinn Loftis